Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...
The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...
and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014. That resulted in false claims for ...
WearOptimo, a healthcare technology company developing next-generation Microwearable sensors for hydration and biomarker monitoring, today introduced its Advisory Board comprised of globally ...
BRISBANE, Australia and NEW YORK, March 11, 2025 /PRNewswire/ -- WearOptimo, a healthcare technology company developing next-generation Microwearable sensors for hydration and biomarker monitoring ...
Pre-Market: 5:58:06 a.m. EDT Loading Chart for BIIB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback